Quality of Life in Lymphoma Patients One Year Post-chemotherapy

Lymphoma Clinical Trial

— QUALIPSO-L  

Official title:

Quality of Life in Lymphoma Patients and Cancer Care Pathway One Year Post-chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04187118
• Other study ID #: RC31/19/0295
• Status: Recruiting
• Start date: January 28, 2020
• Est. completion date: June 2025

Study information

• Verified date: September 2023
• Source: University Hospital, Toulouse
• Contact: Loïc YSEBAERT, MD, PhD
• Phone: 561145940
• Email: ysebaert.loic[@]iuct-oncopole.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Malignant lymphomas are considered as among the most chemo-sensitive cancers. ML are cured in more than 85% of patient, the majority with complete response. After this active phase of treatment, patients are in "after cancer period". Toulouse University Hospital developed since 2006 the Ambulatory Medical Assistance for After Cancer program on lymphoma patient. Ambulatory Medical Assistance for After Cancer is very efficient for detecting physical and psychological complications which impact quality of life. The investigators identified 22% of lymphoma patients who had a reduced quality of life one year after the end of chemotherapy. The present study aims to investigate the evolution of observed complications and identify cancer care pathway which decrease the quality of life reduction risk in patients one year after lymphoma chemotherapy.

Description:

Quality of life, as well anxiety, depression, social isolation, fear of cancer recurrence, post traumatic stress, will be measured in lymphoma patients, after a first line chemotherapy. Care cancer pathway will be also evaluated. Self-administered questionnaires will be performed on website (www.hospitalidee.fr) after inclusion and 12 months after.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: June 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients being in complete response after a first therapy for lymphoma

• Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation

• Patients informed of the study and not opposed to the research

Exclusion Criteria:

• Patients under legal guardian .

• Patients unavailable to formulate non-opposition to the study

Related Conditions & MeSH terms

• Lymphoma

Intervention

Other:
• Quality of life
Quality of life one year post chemo-therapy

Locations

Country	Name	City	State
France	University Hospital Toulouse	Toulouse

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Toulouse	Force Hémato, Hospitalidee

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality of life change: Quality of Life-C30 French version	Health-related quality of life is evaluated by the use of Quality of Life-C30 French version	Change from baseline quality of life at 12 month